HB 725 2025
CODING: Words stricken are deletions; words underlined are additions.
hb725-00
Page 1 of 6
F L O R I D A H O U S E O F R E P R E S E N T A T I V E S
A bill to be entitled 1
An act relating to health insurance coverage for CAR 2
T-cell therapies; creating ss. 627.64198, 627.6614, 3
and 641.3133, F.S.; providing definitions; prohibiting 4
specified individual health insurance policies, group 5
health insurance policies, and health maintenance 6
contracts, respectively, from refusing to contract 7
with in-network health care facilities for the 8
provision of CAR T-cell therapies under certain 9
circumstances; prohibiting such policies and contracts 10
from denying coverage for the therapies under certain 11
circumstances; providing an effective date. 12
13
Be It Enacted by the Legislature of the State of Florida: 14
15
Section 1. Section 627.64198, Florida Sta tutes, is created 16
to read: 17
627.64198 Coverage for CAR T -cell therapies.— 18
(1) As used in this section, the term: 19
(a) "CAR T cell" or "chimeric antigen receptor T -cell" 20
means a patient's own T cell that has been altered in a 21
laboratory, to be used late r for the patient's CAR T -cell 22
therapy, also known as chimeric antigen receptor T -cell therapy. 23
(b) "CAR T-cell therapy" or "chimeric antigen receptor T -24
cell therapy" means a cancer treatment in which a patient 25
HB 725 2025
CODING: Words stricken are deletions; words underlined are additions.
hb725-00
Page 2 of 6
F L O R I D A H O U S E O F R E P R E S E N T A T I V E S
receives his or her CAR T cells, or chimeri c antigen receptor T 26
cells, via infusion so that the T cells can find and attack the 27
patient's cancerous cells. The infusion may be preceded by 28
chemotherapy or radiation therapy. 29
(c) "Health care facility" has the same meaning as the 30
term "licensed facil ity" in s. 395.002. 31
(2)(a) A health insurance policy issued, delivered, or 32
renewed on or after January 1, 2026, in this state which 33
provides coverage for chimeric antigen receptor T -cell therapy 34
may not refuse to contract with a health care facility for the 35
administration of CAR T cells and any medication necessary for 36
the CAR T-cell therapy, and the performance of any procedure 37
necessary for such therapy, in accordance with the guidelines 38
and procedures under a CAR T -cell therapy approved by the United 39
States Food and Drug Administration if the health care facility 40
is included in the health insurance policy's provider network 41
with respect to any other service. 42
(b) A health insurance policy issued, delivered, or 43
renewed on or after January 1, 2026, in th is state which 44
provides coverage for chimeric antigen receptor T -cell therapy 45
may not deny coverage for the administration of CAR T cells and 46
any medication necessary for the CAR T -cell therapy, and the 47
performance of any procedure necessary for such thera py, by a 48
health care facility in accordance with the guidelines and 49
procedures under a CAR T -cell therapy approved by the United 50
HB 725 2025
CODING: Words stricken are deletions; words underlined are additions.
hb725-00
Page 3 of 6
F L O R I D A H O U S E O F R E P R E S E N T A T I V E S
States Food and Drug Administration if the health care facility 51
is included in the health insurance policy's provider network 52
with respect to any other service. 53
Section 2. Section 627.6614, Florida Statutes, is created 54
to read: 55
627.6614 Coverage for CAR T -cell therapies.— 56
(1) As used in this section, the term: 57
(a) "CAR T cell" or "chimeric antigen receptor T -cell" 58
means a patient's own T cell that has been altered in a 59
laboratory, to be used later for the patient's CAR T -cell 60
therapy, also known as chimeric antigen receptor T -cell therapy. 61
(b) "CAR T-cell therapy" or "chimeric antigen receptor T -62
cell therapy" means a cancer treatment in which a patient 63
receives his or her CAR T cells, or chimeric antigen receptor T 64
cells, via infusion so that the T cells can find and attack the 65
patient's cancerous cells. The infusion may be preceded by 66
chemotherapy or radiation therapy . 67
(c) "Health care facility" has the same meaning as the 68
term "licensed facility" in s. 395.002. 69
(2)(a) A group health insurance policy issued, delivered, 70
or renewed on or after January 1, 2026, in this state which 71
provides coverage for chimeric antige n receptor T-cell therapy 72
may not refuse to contract with a health care facility for the 73
administration of CAR T cells and any medication necessary for 74
the CAR T-cell therapy, and the performance of any procedure 75
HB 725 2025
CODING: Words stricken are deletions; words underlined are additions.
hb725-00
Page 4 of 6
F L O R I D A H O U S E O F R E P R E S E N T A T I V E S
necessary for such therapy, in accordance w ith the guidelines 76
and procedures under a CAR T -cell therapy approved by the United 77
States Food and Drug Administration if the health care facility 78
is included in the group health insurance policy's provider 79
network with respect to any other service. 80
(b) A group health insurance policy issued, delivered, or 81
renewed on or after January 1, 2026, in this state which 82
provides coverage for chimeric antigen receptor T -cell therapy 83
may not deny coverage for the administration of CAR T cells and 84
any medication necessary for the CAR T -cell therapy, and the 85
performance of any procedure necessary for such therapy, by a 86
health care facility in accordance with the guidelines and 87
procedures under a CAR T -cell therapy approved by the United 88
States Food and Drug Administ ration if the health care facility 89
is included in the group health insurance policy's provider 90
network with respect to any other service. 91
Section 3. Section 641.3133, Florida Statutes, is created 92
to read: 93
641.3133 Coverage for CAR T -cell therapies.— 94
(1) As used in this section, the term: 95
(a) "CAR T cell" or "chimeric antigen receptor T -cell" 96
means a patient's own T cell that has been altered in a 97
laboratory, to be used later for the patient's CAR T -cell 98
therapy, also known as chimeric antigen rece ptor T-cell therapy. 99
(b) "CAR T-cell therapy" or "chimeric antigen receptor T -100
HB 725 2025
CODING: Words stricken are deletions; words underlined are additions.
hb725-00
Page 5 of 6
F L O R I D A H O U S E O F R E P R E S E N T A T I V E S
cell therapy" means a cancer treatment in which a patient 101
receives his or her CAR T cells, or chimeric antigen receptor T 102
cells, via infusion so that the T cells can find and a ttack the 103
patient's cancerous cells. The infusion may be preceded by 104
chemotherapy or radiation therapy. 105
(c) "Health care facility" has the same meaning as the 106
term "licensed facility" in s. 395.002. 107
(2)(a) A health maintenance contract issued, delivere d, or 108
renewed on or after January 1, 2026, in this state which 109
provides coverage for chimeric antigen receptor T -cell therapy 110
may not refuse to contract with a health care facility for the 111
administration of CAR T cells and any medication necessary for 112
the CAR T-cell therapy, and the performance of any procedure 113
necessary for such therapy, in accordance with the guidelines 114
and procedures under a CAR T -cell therapy approved by the United 115
States Food and Drug Administration if the health care facility 116
is included in the health insurance contract's provider network 117
with respect to any other service. 118
(b) A health insurance contract issued, delivered, or 119
renewed on or after January 1, 2026, in this state which 120
provides coverage for chimeric antigen receptor T -cell therapy 121
may not deny coverage for the administration of CAR T cells and 122
any medication necessary for the CAR T -cell therapy, and the 123
performance of any procedure necessary for such therapy, by a 124
health care facility in accordance with the guidelines an d 125
HB 725 2025
CODING: Words stricken are deletions; words underlined are additions.
hb725-00
Page 6 of 6
F L O R I D A H O U S E O F R E P R E S E N T A T I V E S
procedures under a CAR T -cell therapy approved by the United 126
States Food and Drug Administration if the health care facility 127
is included in the health insurance contract's provider network 128
with respect to any other service. 129
Section 4. This act shall take effect January 1, 2026. 130